Which has better earnings and valuation, TWST or VCYT?

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 21.19 -$77.67M -$2.22 N/A Veracyte $517.15M 6.35 $66.35M $1.41 28.99

Does the media favor TWST or VCYT?

In the previous week, Twist Bioscience had 11 more articles in the media than Veracyte. MarketBeat recorded 17 mentions for Twist Bioscience and 6 mentions for Veracyte. Twist Bioscience's average media sentiment score of 0.59 beat Veracyte's score of 0.44 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 5 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, EXEL or VCYT?

Exelixis has higher revenue and earnings than Veracyte. Exelixis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.44B 5.71 $782.57M $3.18 17.65 Veracyte $517.15M 6.35 $66.35M $1.41 28.99

Is EXEL or VCYT more profitable?

Exelixis has a net margin of 35.33% compared to Veracyte's net margin of 20.37%. Exelixis' return on equity of 42.17% beat Veracyte's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Veracyte 20.37% 9.26% 8.61%

Does the media prefer EXEL or VCYT?

In the previous week, Exelixis had 20 more articles in the media than Veracyte. MarketBeat recorded 26 mentions for Exelixis and 6 mentions for Veracyte. Exelixis' average media sentiment score of 0.67 beat Veracyte's score of 0.44 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Positive Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VCYT or BMRN?

In the previous week, BioMarin Pharmaceutical had 13 more articles in the media than Veracyte. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 6 mentions for Veracyte. BioMarin Pharmaceutical's average media sentiment score of 0.77 beat Veracyte's score of 0.44 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VCYT or MDGL?

In the previous week, Madrigal Pharmaceuticals had 4 more articles in the media than Veracyte. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 6 mentions for Veracyte. Madrigal Pharmaceuticals' average media sentiment score of 0.82 beat Veracyte's score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or VCYT?

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Veracyte. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 6 mentions for Veracyte. Arrowhead Pharmaceuticals' average media sentiment score of 0.98 beat Veracyte's score of 0.44 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Veracyte (VCYT) Competitors

$40.87 -1.16 (-2.76%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$40.86 0.00 (-0.01%)

As of 09/11/2026 07:30 PM Eastern

Compare

VCYT vs. TWST, EXEL, BMRN, MDGL, and ARWR

Should you buy Veracyte stock or one of its competitors? Veracyte's main competitors and comparable companies include Twist Bioscience (TWST), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), and Arrowhead Pharmaceuticals (ARWR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Veracyte compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Veracyte (NASDAQ:VCYT) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Twist Bioscience has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Veracyte has a net margin of 20.37% compared to Twist Bioscience's net margin of -31.66%. Veracyte's return on equity of 9.26% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Veracyte	20.37%	9.26%	8.61%

Twist Bioscience currently has a consensus price target of $98.45, indicating a potential downside of 22.61%. Veracyte has a consensus price target of $55.78, indicating a potential upside of 36.48%. Given Veracyte's stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veracyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.91

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	21.19	-$77.67M	-$2.22	N/A
Veracyte	$517.15M	6.35	$66.35M	$1.41	28.99

In the previous week, Twist Bioscience had 11 more articles in the media than Veracyte. MarketBeat recorded 17 mentions for Twist Bioscience and 6 mentions for Veracyte. Twist Bioscience's average media sentiment score of 0.59 beat Veracyte's score of 0.44 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	5 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Veracyte beats Twist Bioscience on 10 of the 15 factors compared between the two stocks.

How does Veracyte compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Exelixis had 20 more articles in the media than Veracyte. MarketBeat recorded 26 mentions for Exelixis and 6 mentions for Veracyte. Exelixis' average media sentiment score of 0.67 beat Veracyte's score of 0.44 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Positive
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

Exelixis presently has a consensus target price of $50.07, indicating a potential downside of 10.79%. Veracyte has a consensus target price of $55.78, indicating a potential upside of 36.48%. Given Veracyte's stronger consensus rating and higher possible upside, analysts clearly believe Veracyte is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38
Veracyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.91

Exelixis has a net margin of 35.33% compared to Veracyte's net margin of 20.37%. Exelixis' return on equity of 42.17% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Veracyte	20.37%	9.26%	8.61%

Exelixis has higher revenue and earnings than Veracyte. Exelixis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.71	$782.57M	$3.18	17.65
Veracyte	$517.15M	6.35	$66.35M	$1.41	28.99

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 1.6% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Exelixis beats Veracyte on 11 of the 17 factors compared between the two stocks.

How does Veracyte compare to BioMarin Pharmaceutical?

Veracyte (NASDAQ:VCYT) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Veracyte presently has a consensus target price of $55.78, suggesting a potential upside of 36.48%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 35.77%. Given Veracyte's stronger consensus rating and higher probable upside, research analysts plainly believe Veracyte is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.91
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74

BioMarin Pharmaceutical has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.35	$66.35M	$1.41	28.99
BioMarin Pharmaceutical	$3.22B	3.95	$348.90M	$0.37	177.51

In the previous week, BioMarin Pharmaceutical had 13 more articles in the media than Veracyte. MarketBeat recorded 19 mentions for BioMarin Pharmaceutical and 6 mentions for Veracyte. BioMarin Pharmaceutical's average media sentiment score of 0.77 beat Veracyte's score of 0.44 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Veracyte has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Veracyte has a net margin of 20.37% compared to BioMarin Pharmaceutical's net margin of 2.14%. Veracyte's return on equity of 9.26% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

Veracyte beats BioMarin Pharmaceutical on 10 of the 17 factors compared between the two stocks.

How does Veracyte compare to Madrigal Pharmaceuticals?

Veracyte (NASDAQ:VCYT) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Veracyte has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its stock price is 198% less volatile than the broader market.

Veracyte has a net margin of 20.37% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Veracyte's return on equity of 9.26% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Veracyte has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.35	$66.35M	$1.41	28.99
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A

In the previous week, Madrigal Pharmaceuticals had 4 more articles in the media than Veracyte. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 6 mentions for Veracyte. Madrigal Pharmaceuticals' average media sentiment score of 0.82 beat Veracyte's score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 1.6% of Veracyte shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Veracyte presently has a consensus price target of $55.78, suggesting a potential upside of 36.48%. Madrigal Pharmaceuticals has a consensus price target of $699.64, suggesting a potential upside of 30.90%. Given Veracyte's stronger consensus rating and higher probable upside, research analysts plainly believe Veracyte is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.91
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Veracyte beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Veracyte compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Veracyte has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$669.50M	17.43	-$1.63M	-$2.25	N/A
Veracyte	$517.15M	6.35	$66.35M	$1.41	28.99

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

Arrowhead Pharmaceuticals presently has a consensus price target of $99.15, indicating a potential upside of 19.68%. Veracyte has a consensus price target of $55.78, indicating a potential upside of 36.48%. Given Veracyte's stronger consensus rating and higher possible upside, analysts clearly believe Veracyte is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Veracyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.91

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Veracyte. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 6 mentions for Veracyte. Arrowhead Pharmaceuticals' average media sentiment score of 0.98 beat Veracyte's score of 0.44 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Veracyte has a net margin of 20.37% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Veracyte's return on equity of 9.26% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Veracyte	20.37%	9.26%	8.61%

Summary

Veracyte beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCYT vs. The Competition

Export

Metric	Veracyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.38B	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	28.99	14.18	274.95	25.29
Price / Sales	6.35	1,477.55	656.56	98.96
Price / Cash	28.22	106.68	77.04	51.44
Price / Book	2.47	15.12	10.33	6.20
Net Income	$66.35M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-3.90%	-4.34%	-3.32%	-2.35%
1 Month Performance	-8.53%	-0.02%	-0.41%	-2.77%
1 Year Performance	32.35%	40.64%	19.21%	7.63%

Veracyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCYT Veracyte	4.3707 of 5 stars	$40.87 -2.8%	$55.78 +36.5%	+28.3%	$3.38B	$517.15M	28.99	755	Analyst Upgrade
TWST Twist Bioscience	1.7955 of 5 stars	$139.00 -1.7%	$98.30 -29.3%	+396.8%	$8.87B	$376.57M	N/A	990	News Coverage Analyst Forecast
EXEL Exelixis	2.4957 of 5 stars	$54.64 +0.3%	$50.07 -8.4%	+43.6%	$13.49B	$2.32B	17.18	1,077	Trending News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.6226 of 5 stars	$65.23 +0.9%	$88.92 +36.3%	+17.5%	$12.52B	$3.22B	176.30	3,221	Analyst Forecast
MDGL Madrigal Pharmaceuticals	3.2807 of 5 stars	$540.03 +1.2%	$699.64 +29.6%	+21.6%	$12.33B	$958.40M	N/A	90	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCYT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veracyte (VCYT) Competitors

VCYT vs. TWST, EXEL, BMRN, MDGL, and ARWR

How does Veracyte compare to Twist Bioscience?

Summary

How does Veracyte compare to Exelixis?

Summary

How does Veracyte compare to BioMarin Pharmaceutical?

Summary

How does Veracyte compare to Madrigal Pharmaceuticals?

Summary

How does Veracyte compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veracyte (VCYT) Competitors

VCYT vs. TWST, EXEL, BMRN, MDGL, and ARWR

How does Veracyte compare to Twist Bioscience?

Which has more volatility & risk, TWST or VCYT?

Is TWST or VCYT more profitable?

Do analysts rate TWST or VCYT?

Which has better earnings and valuation, TWST or VCYT?

Does the media favor TWST or VCYT?

Summary

How does Veracyte compare to Exelixis?

Does the media prefer EXEL or VCYT?

Which has more risk and volatility, EXEL or VCYT?

Do analysts rate EXEL or VCYT?

Is EXEL or VCYT more profitable?

Which has higher valuation and earnings, EXEL or VCYT?

Do insiders & institutionals hold more shares of EXEL or VCYT?

Summary

How does Veracyte compare to BioMarin Pharmaceutical?

Do analysts rate VCYT or BMRN?

Which has better earnings & valuation, VCYT or BMRN?

Does the media refer more to VCYT or BMRN?

Do insiders and institutionals hold more shares of VCYT or BMRN?

Which has more risk & volatility, VCYT or BMRN?

Is VCYT or BMRN more profitable?

Summary

How does Veracyte compare to Madrigal Pharmaceuticals?

Which has more volatility and risk, VCYT or MDGL?

Is VCYT or MDGL more profitable?

Which has higher earnings and valuation, VCYT or MDGL?

Does the media favor VCYT or MDGL?

Do insiders & institutionals have more ownership in VCYT or MDGL?

Do analysts prefer VCYT or MDGL?

Summary

How does Veracyte compare to Arrowhead Pharmaceuticals?

Which has preferable earnings & valuation, ARWR or VCYT?

Which has more volatility & risk, ARWR or VCYT?

Do analysts recommend ARWR or VCYT?

Does the media refer more to ARWR or VCYT?

Do institutionals and insiders believe in ARWR or VCYT?

Is ARWR or VCYT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools